Harvard Bioscience Inc vs. 10x Genomics, Inc. Class A Common Stock
HBIO
Harvard Bioscience Inc
$7.58 +0.40%
VS TXG10x Genomics, Inc. Class A Common Stock
$64.72 +1.44%
Harvard Bioscience Inc and 10x Genomics, Inc. Class A Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| HBIO | TXG | |
|---|---|---|
| Market Cap | $34.37 million | $8.43 billion |
| Revenue (TTM) | $87.81 million | $616.91 million |
| Net Income (TTM) | $-10,412,000 | $-75,125,000 |
TXG leads on 2 of 3 size & scale factors.
Valuation
| HBIO | TXG | |
|---|---|---|
| Price / Book | 4.63 | 10.21 |
| Price / Sales | 0.39 | 13.67 |
HBIO leads on 2 of 2 valuation factors.
Profitability
| HBIO | TXG | |
|---|---|---|
| Net Margin | -11.86% | -12.18% |
| Return on Equity | -140.36% | -9.10% |
HBIO and TXG split the profitability factors evenly.
Risk & Sentiment
| HBIO | TXG | |
|---|---|---|
| Short Interest | 11.71% | 0.42% |
TXG leads on 1 of 1 risk & sentiment factors.
Dig deeper: HBIO overview, HBIO financials, TXG overview, TXG financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.